Chemotherapy-Enriched THBS2-Deficient Cancer Stem Cells Drive Hepatocarcinogenesis through Matrix Softness Induced...

Area of Science:

• Oncology
• Cancer Biology
• Tumor Microenvironment

Background:

• The tumor microenvironment significantly influences cancer progression, but detailed mechanisms remain unclear.
• Understanding the role of cancer stem cells (CSCs) in shaping the physical tumor microenvironment is crucial for developing effective therapies.

Purpose of the Study:

• To investigate the role of chemotherapy-enriched CD133+ liver CSCs with THBS2 deficiency in hepatocellular carcinoma (HCC) progression.
• To elucidate the mechanisms by which these CSCs remodel the extracellular matrix (ECM) and impact tumor behavior.

Main Methods:

• Analysis of chemotherapy-enriched CD133+ liver CSCs and their interaction with the ECM.
• Assessment of matrix metalloproteinase (MMP) activity, collagen degradation, and matrix stiffness.
• Correlation of THBS2 deficiency and CSC levels with clinical HCC patient data, including survival and tumor characteristics.

Main Results:

• THBS2-deficient CD133+ liver CSCs promote aggressive HCC by remodeling the ECM, increasing matrix softness, and enhancing stemness and drug resistance.
• A positive feedback loop exists where soft spots in HCC tumors are maintained by CD133+ cells with reduced THBS2 secretion due to histone modification.
• Clinically, THBS2 deficiency correlates with poor HCC survival, decreased collagen, and an invasive tumor front.

Conclusions:

• THBS2-deficient liver CSCs create a permissive microenvironment that drives HCC aggressiveness and metastasis.
• Targeting cancer stemness and the ECM remodeling by these cells offers potential therapeutic strategies for HCC.
• THBS2 deficiency serves as a prognostic marker for HCC, indicating a more invasive tumor phenotype.